Reading XOMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XOMA free→Reading XOMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track XOMA free→QuarterlyIQ Insights · XOMA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On June 12, 2026, XOMA Royalty Corporation (the “Company”) issued a press release announcing that it expects the closing of the previously announced acquisition of XOMA Royalty Holdings Corporation (“HoldCo”) by Ligand Pharmaceuticals Incorporated (“Ligand”) to occur on or about July 14, 2026, subject to the satisfaction or waiver of the remaining conditions to closing set forth in the Agreement and Plan of Merger, dated as of April 27, 2026, as amended by that certa…
relating to the Redemption and the Notices is for informational purposes only and does not constitute an offer to buy or a solicitation of an offer to sell any shares of Preferred Stock, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. Such information is not itself a notice of redemption with respect to the Preferred Stock, and the Redemption will be made in accordance with the terms of the applicable…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2026, XOMA Royalty Corporation (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which point the polls were closed on the proposals contained in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026 (the “Proxy Stateme…
Entry Into a Material Definitive Agreement. As previously disclosed, on April 27, 2026, XOMA Royalty Corporation, a Nevada corporation (the “ Company ” or “ XOMA Royalty ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Parent ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”), pursuant to which, and upon the terms and subj…
Entry into a Material Definitive Agreement. On April 27, 2026, XOMA Royalty Corporation, a Nevada corporation (the “ Company ” or “ XOMA Royalty ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Parent ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”), pursuant to which, and upon the terms and subject to the conditions the…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Royalty (“ Merger Sub ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions th…
Other Events. On April 27, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. Additional Information and Where to Find It In connection with the proposed acquisition, XOMA Royalty will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed acquisition. The definitive proxy statement will…
Results of Operations and Financial Condition. On March 18, 2026, XOMA Royalty Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. The information set forth on pages 10-11 of the updated corporate presentation furnished under
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Royalty (“ Merger Sub ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions th…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA ”) entered into a share purchase agreement, dated August 3, 2025 (as amended to date, the “ Purchase Agreement ”), with LAVA Therapeutics N.V., a public limited liability company ( naamloze vennootschap ) organized under the laws of The Netherlands (the “ LAVA ”). In accordance with the Purchase Agreement, on August 15, 2025, XOMA commenced a tender offer (the “ Offer ”) to purchase a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Jeffrey Trigilio as Chief Financial Officer Effective January 12, 2026 (the “Effective Date”), the board of directors (the “Board”) of XOMA Royalty Corporation, a Nevada corporation (the “Company”), appointed Jeffrey Trigilio to succeed Thomas Burns as the Company’s Chief Financial Officer. Mr. Trigilio, age 41, previously served in…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA ”) entered into a transaction agreement, dated August 20, 2025 (the “ Transaction Agreement ”), with Mural Oncology plc, a public limited company organized under the laws of Ireland (“ Mural ”), and XRA 5 Corp., a Delaware corporation and wholly-owned subsidiary of XOMA (“ Merger Sub ”), pursuant to which Merger Sub has agreed to acquire the entire issued and to be issued share capita…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA ”) entered into a share purchase agreement, dated August 3, 2025 (as amended to date, the “ Purchase Agreement ”), with LAVA Therapeutics N.V., a public limited liability company ( naamloze vennootschap ) organized under the laws of The Netherlands (the “ LAVA ”). In accordance with the Purchase Agreement, on August 15, 2025, XOMA commenced a tender offer (the “ Offer ”) to purchase a…
Results of Operations and Financial Condition. On November 12, 2025, XOMA Royalty Corporation issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section…
Entry Into a Material Definitive Agreement Common Stock Sales Agreement On October 3, 2025, XOMA Royalty Corporation (the “ Company ”) entered into an “at the market” sales agreement (the “ Common Stock Sales Agreement ”) with Leerink Partners LLC (“ Leerink ”), pursuant to which the Company may offer and sell from time to time up to $75,000,000 of shares of the Company’s common stock, par value $0.0075 (the “ Common Shares ”), through Leerink, as the Company’s sales agent. Sales of the Commo…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA ”) entered into an Agreement and Plan of Merger, dated August 4, 2025 (the “ Merger Agreement ”), with HilleVax, Inc., a Delaware corporation (“ HilleVax ”), and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA (“ Merger Sub ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on September 16, 2025, XOMA and Merger Su…
Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA ”) entered into an Agreement and Plan of Merger, dated June 26, 2025 (the “ Merger Agreement ”), with Turnstone Biologics Corp., a Delaware corporation (“ Turnstone ”), and XRA 3 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA (“ Merger Sub ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 8, 2025, XOMA comple…
Results of Operations and Financial Condition. On August 13, 2025, XOMA Royalty Corporation issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting, the Company’s stockholders approved the Company’s Amended and Restated 2010 Long Term Incentive and Stock Award Plan (as so amended, the “Plan”), which increases the shares of common stock available for issuance under the Plan by 880,000 shares, prohibits payment of dividends and dividend equivalents on unvested awards and ma…
Material Modification to Rights of Shareholders. At the Annual Meeting, the Company’s stockholders approved the proposed reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) by means of a plan of conversion (the “Plan of Conversion”), as described in the Proxy Statement. Pursuant to the Plan of Conversion, the Company effected the Reincorporation as of May 30, 2025 by filing: (i) a certificate of conversion with the Secretary of State of the…
Results of Operations and Financial Condition. On May 13, 2025, XOMA Royalty Corporation issued a press release announcing its financial results for the fiscal quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of th…
Results of Operations and Financial Condition. On March 17, 2025, XOMA Royalty Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 1…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.